FDA 483 - Delpharm Dijon - May 31, 2024

An FDA inspection of Delpharm Dijon, a sterile drug manufacturer in Quetigny, France, revealed significant deficiencies in their manufacturing processes. Observations included inadequate master production and control records lacking theoretical yield and percentage calculations, and a failure to establish appropriate time limits for production phases to ensure drug product quality.